TY - JOUR
T1 - A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab
T2 - BRB study
AU - Matsumoto, Kimihiro
AU - Takayama, Nobuyuki
AU - Aisa, Yoshinobu
AU - Ueno, Hironori
AU - Hagihara, Masao
AU - Watanabe, Kentaro
AU - Nakaya, Aya
AU - Chen, Kenko
AU - Shimizu, Takayuki
AU - Tsukada, Yuiko
AU - Yamada, Yuji
AU - Nakazato, Tomonori
AU - Ishida, Akaru
AU - Miyakawa, Yoshitaka
AU - Yokoyama, Kenji
AU - Nakajima, Hideaki
AU - Masuda, Yoshihiro
AU - Yano, Takahiro
AU - Okamoto, Shinichiro
N1 - Publisher Copyright:
© 2015, The Japanese Society of Hematology.
PY - 2015/6/11
Y1 - 2015/6/11
N2 - To evaluate the efficacy and safety of a combined regimen of bendamustine (B) and rituximab (R) in Japanese patients with relapsed/refractory (r/r) indolent B-cell non-Hodgkin lymphomas (B-NHLs) and mantle cell lymphoma (MCL). Patients aged 20–79 years with pathologically confirmed B-NHLs or MCL, which were r/r after 1–2 R-containing regimens, were included in this study. The BR regimen consisted of B (90 mg/m2) for two consecutive days and R (375 mg/m2) on day 1, 2, or 3. The course was repeated every 4 weeks for up to four cycles. Fifty-three patients were enrolled in this study and analyzed. The diagnosis included follicular lymphoma (FL) (77 %), mucosa-associated lymphoid tissue lymphoma (13 %) and others (10 %). Forty-seven (90 %) patients completed four cycles of treatment as per schedule. Best overall response rate (ORR) and complete response rate (CRR) was 94 and 71 %, respectively (for FL, ORR 95 % and CRR 80 %). The treatment was well tolerated and the primary toxicity was myelosuppression; the incidence of grade 3/4 leukopenia and neutropenia were 42 and 40 %, respectively. There were no grade 5 toxicities. The BR regimen is safe in Japanese patients with r/r indolent B-NHLs and MCL, and is effective for those with r/r indolent B-NHLs. For the evaluation of late toxicity, especially infection, longer follow-up of this cohort is needed.
AB - To evaluate the efficacy and safety of a combined regimen of bendamustine (B) and rituximab (R) in Japanese patients with relapsed/refractory (r/r) indolent B-cell non-Hodgkin lymphomas (B-NHLs) and mantle cell lymphoma (MCL). Patients aged 20–79 years with pathologically confirmed B-NHLs or MCL, which were r/r after 1–2 R-containing regimens, were included in this study. The BR regimen consisted of B (90 mg/m2) for two consecutive days and R (375 mg/m2) on day 1, 2, or 3. The course was repeated every 4 weeks for up to four cycles. Fifty-three patients were enrolled in this study and analyzed. The diagnosis included follicular lymphoma (FL) (77 %), mucosa-associated lymphoid tissue lymphoma (13 %) and others (10 %). Forty-seven (90 %) patients completed four cycles of treatment as per schedule. Best overall response rate (ORR) and complete response rate (CRR) was 94 and 71 %, respectively (for FL, ORR 95 % and CRR 80 %). The treatment was well tolerated and the primary toxicity was myelosuppression; the incidence of grade 3/4 leukopenia and neutropenia were 42 and 40 %, respectively. There were no grade 5 toxicities. The BR regimen is safe in Japanese patients with r/r indolent B-NHLs and MCL, and is effective for those with r/r indolent B-NHLs. For the evaluation of late toxicity, especially infection, longer follow-up of this cohort is needed.
KW - Bendamustine
KW - Indolent B-cell lymphoma
KW - Mantle cell lymphoma
KW - Refractory/relapsed
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84930577707&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930577707&partnerID=8YFLogxK
U2 - 10.1007/s12185-015-1767-3
DO - 10.1007/s12185-015-1767-3
M3 - Article
C2 - 25783753
AN - SCOPUS:84930577707
SN - 0925-5710
VL - 101
SP - 554
EP - 562
JO - International journal of hematology
JF - International journal of hematology
IS - 6
ER -